(NYSE: LLY) Eli Lilly & Co's forecast annual revenue growth rate of 12.82% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 5.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Eli Lilly & Co's revenue in 2025 is $59,419,800,000.On average, 31 Wall Street analysts forecast LLY's revenue for 2025 to be $58,868,101,164,633, with the lowest LLY revenue forecast at $56,065,983,708,885, and the highest LLY revenue forecast at $61,787,446,206,249. On average, 31 Wall Street analysts forecast LLY's revenue for 2026 to be $69,795,792,011,796, with the lowest LLY revenue forecast at $62,085,242,089,704, and the highest LLY revenue forecast at $76,609,172,748,495.
In 2027, LLY is forecast to generate $80,641,234,472,100 in revenue, with the lowest revenue forecast at $71,330,149,849,407 and the highest revenue forecast at $90,646,230,772,431.